Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187949
Title: | Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry |
Author: | Ramos Rincon, Jose Manuel López Carmona, María Dolores Cobos Palacios, Lidia López Sampalo, Almudena Rubio Rivas, Manuel Martín Escalante, María Dolores Cossio Tejido, Santiago de Taboada-Martínez, María Luisa Muiño Miguez, Antonio Areses Manrique, Maria Martinez Cilleros, Carmen Tuñón de Almeida, Carlota Abella Vázquez, Lucy Martínez Gonzalez, Angel Luís Díez García, Luis Felipe Ripper, Carlos Jorge Asensi, Victor Martinez Pascual, Angeles Guisado Vasco, Pablo Lumbreras Bermejo, Carlos Gómez Huelgas, Ricardo The Semi-covid-19 Network |
Keywords: | COVID-19 SARS-CoV-2 Persones grans Malalts hospitalitzats COVID-19 SARS-CoV-2 Older people Hospital patients |
Issue Date: | 29-Jun-2022 |
Publisher: | MDPI AG |
Abstract: | Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients >= 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were >= 80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29-0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22-0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm11133769 |
It is part of: | Journal of Clinical Medicine, 2022, vol. 11, num. 13, p. 3769 |
URI: | http://hdl.handle.net/2445/187949 |
Related resource: | https://doi.org/10.3390/jcm11133769 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-11-03769-v2.pdf | 303.18 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License